Recombinant Rat CX3C chemokine receptor 1 (Cx3cr1)

What is CX3CR1 and what is its primary ligand?

CX3CR1 is a G protein-coupled receptor that serves as the specific receptor for the chemokine CX3CL1 (also known as Fractalkine). Unlike other chemokine relationships, CX3CL1 is the only known ligand for CX3CR1, making this a unique one-to-one receptor-ligand interaction. CX3CL1 is distinctive among chemokines as it exists in both membrane-bound and soluble forms, with the membrane-bound form containing a chemokine domain attached to a mucin-like stalk . The CX3CR1-CX3CL1 axis plays crucial roles in cell adhesion, migration, and signaling in various physiological and pathological conditions.

How does rat CX3CR1 structurally compare to human and mouse orthologs?

Rat CX3CR1 shares significant structural homology with its human and mouse counterparts. While the search results don't provide specific sequence identity percentages for the receptor itself, we can infer from the ligand data that there is substantial conservation. The CX3CL1 ligand shows approximately 83% sequence identity between rat and human/mouse variants (excluding the stalk region) . This high degree of conservation suggests similar functional domains in the receptor across species, though researchers should be aware of species-specific differences that might affect experimental outcomes when transitioning between model systems.

What is the tissue distribution pattern of CX3CR1 in rats?

In rats, CX3CR1 is predominantly expressed on microglia in the central nervous system, where it mediates neuron-microglia communication through interaction with neuronally-expressed CX3CL1 . Outside the CNS, CX3CR1 is expressed on various immune cells including monocytes, macrophages, natural killer cells, and certain T-cell subsets. The receptor is also found in kidney tissue, where it plays a role in renal macrophage survival and function during infection, as demonstrated in candidiasis models . This distribution pattern makes CX3CR1 particularly important in both neuroinflammatory conditions and peripheral immune responses.

What are the validated methods for detecting CX3CR1 expression in rat tissue samples?

Several validated methods can effectively detect CX3CR1 expression in rat tissues:

• Immunohistochemistry/Immunofluorescence: Using specific antibodies against CX3CR1, this approach allows visualization of receptor distribution in tissue sections. As shown in the search results, immunofluorescence staining has been successfully used to detect CX3CR1 (green) alongside CX3CL1 (red) in rat hippocampus .

• Western Blot Analysis: This technique quantifies CX3CR1 protein expression in tissue lysates. Research cited in the search results demonstrates its effective use in measuring CX3CR1 expression in hippocampal samples from different experimental groups .

• RT-PCR/qPCR: These methods detect CX3CR1 mRNA expression levels and are particularly useful when examining transcriptional regulation.

• Flow Cytometry: This approach is valuable for quantifying CX3CR1 expression on specific cell populations isolated from rat tissues.

For optimal results, researchers should validate antibody specificity using appropriate controls, including CX3CR1-knockout tissues when available.

How can I establish a functional assay to study CX3CR1 activation in rat cell models?

Establishing a functional assay for CX3CR1 activation requires:

• Chemotaxis Assays: The search results describe a method using BaF3 mouse pro-B cells transfected with human CX3CR1 to measure migration in response to recombinant rat CX3CL1 . A similar approach can be adapted using rat cells expressing CX3CR1. Migration can be quantified using Resazurin or other viability markers to count cells that migrate through a membrane in response to CX3CL1 gradients.

• Calcium Flux Assays: CX3CR1 activation triggers intracellular calcium mobilization, which can be measured using calcium-sensitive fluorescent dyes.

• Phosphorylation Studies: Assess activation of downstream signaling molecules (ERK, AKT, etc.) via Western blotting following CX3CL1 stimulation.

• Receptor Internalization: Monitor receptor endocytosis following ligand binding using fluorescently-labeled CX3CL1.

• Neutralization Controls: Include anti-CX3CL1 antibodies (like AF537) to confirm specificity by neutralizing the observed effects .

The ED50 for rat CX3CL1-induced chemotaxis is typically 3-18 ng/mL , which serves as a useful reference range when designing dose-response experiments.

What approaches are effective for studying CX3CR1-CX3CL1 interactions in vivo in rat models?

Effective approaches for studying CX3CR1-CX3CL1 interactions in vivo include:

• Genetic Models: While the search results mention CX3CR1-deficiency in mouse models, similar approaches using CRISPR/Cas9 or other gene editing technologies can be applied to rats to study receptor function through knockout or knockin strategies.

• Neutralizing Antibodies: Administration of anti-CX3CL1 antibodies (such as AF537) can block the interaction between CX3CL1 and CX3CR1, allowing assessment of physiological outcomes in various disease models .

• Viral Vector-Mediated Manipulation: The search results describe using lenti-pre-AMO-miR-195 to upregulate CX3CL1 and CX3CR1 expression in rat hippocampus . Similar viral approaches can be used to modulate receptor expression.

• In Vivo Imaging: Techniques like intravital microscopy using fluorescently labeled antibodies or ligands can track CX3CR1-expressing cells and their interactions in live animals.

• Pharmacological Interventions: CX3CR1 antagonists or mimetics can be administered to assess receptor function in disease models.

When designing in vivo experiments, researchers should carefully consider appropriate controls, dosing, timing, and delivery methods to ensure interpretable results.

How does the CX3CR1-CX3CL1 axis contribute to synaptic plasticity in the rat hippocampus?

The CX3CR1-CX3CL1 axis plays a significant role in hippocampal synaptic plasticity as evidenced by several studies:

• Memory-Associated Plasticity: CX3CL1 is upregulated in the rat hippocampus during memory-associated synaptic plasticity, suggesting its importance in learning and memory processes .

• Microglial Regulation: CX3CR1-expressing microglia respond to neuronal CX3CL1 signals, which modulates microglial activation states. Research indicates that selective microglial activation facilitates synaptic strength .

• Homeostatic Regulation: The CX3CL1/CX3CR1 signaling pathway contributes to the homeostatic regulation of synaptic function, with disruptions potentially contributing to cognitive impairments.

• Interaction with Other Chemokines: Studies have shown that CXCL12 regulates CX3CL1 homeostasis in cortical neurons, demonstrating that chemokine crosstalk influences synaptic function .

Methodologically, researchers investigating these mechanisms should employ electrophysiological techniques (such as field potential recordings or patch-clamp) alongside molecular analyses to correlate CX3CR1-CX3CL1 signaling with functional synaptic changes.

What role does CX3CR1 play in neuroinflammation and neurodegeneration in rat models?

CX3CR1 plays complex roles in neuroinflammation and neurodegeneration:

• Microglial Phenotype Regulation: CX3CR1 signaling influences microglial activation states. Disruption of this signaling can exacerbate neuroinflammation, as shown in models of Parkinson's disease where CX3CR1-deficiency worsens α-synuclein-A53T induced neuroinflammation and neurodegeneration .

• Neuroprotection vs. Neurotoxicity: The role of CX3CR1 can be context-dependent. In some models, intact CX3CR1 signaling is neuroprotective by restraining microglial activation, while in others, CX3CR1 may contribute to pathology.

• Cerebral Hypoperfusion Models: In 2VO (two-vessel occlusion) rat models that mimic chronic cerebral hypoperfusion, both CX3CL1 and CX3CR1 expression are upregulated in the hippocampus, suggesting their involvement in the response to ischemic injury .

• MicroRNA Regulation: MiR-195 has been shown to regulate CX3CR1 expression, with lenti-pre-AMO-miR-195 upregulating both CX3CL1 and CX3CR1 in rat hippocampus, providing a potential therapeutic target .

When designing experiments to investigate these relationships, researchers should carefully consider time course analyses, cell-specific markers, and multiple measures of neurodegeneration alongside CX3CR1 manipulation.

How does noradrenaline influence CX3CR1-CX3CL1 signaling in neuronal-microglial communication?

The search results indicate that noradrenaline induces CX3CL1 production and release by neurons , which has several implications for neuronal-microglial communication:

• Noradrenergic Regulation: Noradrenaline can modulate neuron-microglia interactions by stimulating neuronal CX3CL1 release, which then binds to CX3CR1 on microglia.

• Stress Response Integration: Since noradrenaline is a key mediator of stress responses, this mechanism may link stress to microglial activation states and neuroinflammation.

• Methodological Approach: To study this phenomenon, researchers have used ICC (immunocytochemistry) and Western blotting techniques on rat neuronal cultures treated with noradrenaline .

For comprehensive investigation of this pathway, researchers should:

• Use selective adrenergic receptor antagonists to identify specific receptor subtypes involved

• Employ calcium imaging to track signaling dynamics

• Utilize co-culture systems with neurons and microglia to observe functional outcomes of this regulation

• Consider in vivo approaches with local noradrenaline administration or manipulation of noradrenergic neurons

What is the role of CX3CR1 in rat models of retinal degeneration?

CX3CR1 plays a significant role in retinal degeneration models through regulation of microglial activity:

• Microglial Phagocytosis: The search results indicate that microglial phagocytosis and activation underlying photoreceptor degeneration are regulated by CX3CL1-CX3CR1 signaling in a mouse model of retinitis pigmentosa . Similar mechanisms likely operate in rat models.

• Diabetic Retinopathy: In streptozotocin-induced diabetic rats, oxidative stress and inflammatory mediators in the retina are modulated by the CX3CR1-CX3CL1 axis, which can be targeted by therapeutic interventions such as astaxanthin .

• Experimental Approaches: Researchers have successfully used immunohistochemistry (IHC-P) and Western blot techniques to assess CX3CR1 expression in retinal tissues .

When designing studies to investigate CX3CR1 in retinal degeneration, researchers should consider:

• Specific labeling of microglial populations

• Functional assays of microglial phagocytosis

• In vivo imaging techniques to track microglial dynamics

• Correlation of CX3CR1 expression with disease progression markers

How does CX3CR1 contribute to renal immune responses in rat infection models?

CX3CR1 plays an important role in renal immune responses during infection:

• Macrophage Survival: The search results indicate that CX3CR1-dependent renal macrophage survival promotes Candida control and host survival . This suggests that CX3CR1 signaling supports tissue-resident macrophage function in kidney infection models.

• Immunohistochemical Analysis: Researchers have used immunohistochemistry on kidney tissue samples from transgenic mice to assess CX3CR1 expression patterns during infection . Similar approaches can be applied to rat models.

For effective investigation of CX3CR1's role in renal immunity, researchers should:

• Use flow cytometry to quantify and phenotype CX3CR1+ renal immune cells

• Employ kidney-specific CX3CR1 manipulation (e.g., conditional knockouts or RNA interference)

• Assess kidney function parameters alongside immune responses

• Consider cross-talk between CX3CR1+ cells and other immune and stromal cell populations

What methodologies are most effective for studying the role of CX3CR1 in nociception and pain processing?

Based on the search results, several approaches have proven effective for studying CX3CR1's role in nociception:

• Cerebrospinal Fluid-Contacting Nucleus: Research has shown that the cerebrospinal fluid-contacting nucleus mediates nociception via release of fractalkine (CX3CL1) . This suggests examining this specialized nucleus when studying CX3CR1-mediated pain pathways.

• Neutralization Studies: Researchers have used neutralizing antibodies against CX3CL1 in rat models to block CX3CR1 activation and assess effects on pain perception .

• Electrophysiological Recordings: Studies have employed methods like recording from spinal cord slices to assess how CX3CR1-CX3CL1 signaling modulates synaptic strength in pain pathways .

For comprehensive investigation of CX3CR1 in pain models, researchers should:

• Combine behavioral pain assessments with molecular and cellular analyses

• Use cell-specific genetic approaches to manipulate CX3CR1 in defined cell populations

• Consider the role of CX3CR1 in both acute and chronic pain models

• Examine interactions between CX3CR1 signaling and established pain modulatory systems

• Employ pharmacological interventions with appropriate controls to confirm target specificity

How can I optimize recombinant rat CX3CL1 for functional studies of CX3CR1?

Optimizing recombinant rat CX3CL1 for functional studies requires attention to several technical factors:

• Protein Domain Selection: The search results indicate that the chemokine domain of CX3CL1 (Gln25-Gly100) is sufficient for receptor activation . Using this defined domain rather than the full-length protein (which includes the mucin-like stalk) may provide more consistent results for soluble receptor activation studies.

• Reconstitution Protocol: The search results recommend reconstituting lyophilized CX3CL1 at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin, or in carrier-free format depending on the application .

• Storage Considerations: Use a manual defrost freezer and avoid repeated freeze-thaw cycles to maintain protein activity .

• Effective Dosing: The ED50 for rat CX3CL1-induced chemotaxis is typically 3-18 ng/mL , which provides a reference range for experimental design.

• Carrier Protein Considerations: For applications where the presence of BSA might interfere, carrier-free formulations are available .

When designing functional assays, researchers should include appropriate positive and negative controls, perform dose-response assessments, and validate activity in relevant cell systems expressing rat CX3CR1.

What are the most critical technical challenges in developing CX3CR1-targeted therapeutic approaches for neuroinflammatory conditions?

Developing CX3CR1-targeted therapeutics faces several critical challenges:

• Cell-Type Specificity: Since CX3CR1 is expressed on multiple immune cell types, achieving cell-specific targeting is challenging but essential to avoid unwanted effects on beneficial CX3CR1-mediated processes.

• Context-Dependent Functions: As shown in models of Parkinson's disease, CX3CR1 deficiency can exacerbate neuroinflammation , but in other contexts, CX3CR1 signaling might promote inflammation. This dichotomy complicates therapeutic development.

• Blood-Brain Barrier (BBB) Penetrance: Ensuring that CX3CR1-targeting agents effectively cross the BBB remains a significant challenge for CNS applications.

• Species Differences: While rat and human CX3CL1 share approximately 83% sequence identity , species-specific differences in CX3CR1 structure and function may complicate translation from rodent models to humans.

• Temporal Considerations: The appropriate timing for CX3CR1 modulation may differ across disease stages, requiring precise temporal control of therapeutic intervention.

Researchers addressing these challenges should employ comprehensive pharmacokinetic/pharmacodynamic analyses, consider combination approaches that target multiple aspects of neuroinflammation, and develop biomarkers that predict therapeutic response.

How do post-translational modifications of CX3CR1 affect its function and detection in experimental systems?

While the search results don't specifically address post-translational modifications (PTMs) of CX3CR1, several considerations are important:

• Phosphorylation: As a G protein-coupled receptor, CX3CR1 likely undergoes regulatory phosphorylation that affects signaling and internalization. Researchers should consider using phospho-specific antibodies or phosphoproteomic approaches to characterize these modifications.

• Glycosylation: N-linked glycosylation can affect receptor trafficking and ligand binding. Enzymatic deglycosylation experiments can help assess the impact of glycosylation on CX3CR1 function.

• Ubiquitination: This modification often regulates receptor degradation and trafficking. Analysis of ubiquitination patterns under different conditions may provide insights into receptor turnover.

• Detection Challenges: PTMs can affect antibody binding, potentially leading to false negative results in immunodetection methods. Researchers should validate antibodies using multiple detection approaches and consider using epitope tags when studying modified forms of the receptor.

• Functional Impact: Different PTMs may alter CX3CR1's affinity for CX3CL1, coupling to downstream signaling pathways, or interaction with regulatory proteins. Mutagenesis of potential modification sites can help determine their functional significance.

Researchers investigating CX3CR1 PTMs should employ mass spectrometry approaches for comprehensive modification mapping, develop site-specific antibodies for key modifications, and correlate modification patterns with functional outcomes in relevant physiological and pathological contexts.

Comparative Properties of Recombinant Rat CX3CL1 Formulations for CX3CR1 Studies

Table compiled from product specifications for recombinant rat CX3CL1 (catalog #537-FT/CF)

CX3CR1 and CX3CL1 Expression Changes in Rat Hippocampus Under Different Conditions

Table compiled from research findings reported in search results

CX3CR1-Related Antibodies and Their Validated Applications in Rat Studies

Table compiled from antibody information in search results